

You're Part of Something Big

Issue 4
Winter 2026

It's time to share how enrollment is going. We gathered this information in January 2026 to share with you. These details are about people in Phase 2 who are getting anti-TNF treatment (adalimumab or infliximab).

453 children and adolescents were in Phase 2 and getting anti-TNF treatment.

About
13% are
under 10
years old.

64% are
boys.
36% are
girls.

The
average
age is
about 12.



Enrollment is planned to end by Labor Day 2026.

On the map, you can also see all the states and provinces in CAMEO.

Thank You for Sending in Your Poo

Your stool, or poop, is important in CAMEO. Here are some reminders about stool collection:

Stool has markers for inflammation. Genes and small particles, like bacteria, are also studied. These are all important for understanding and discovering more about human health.

You give us stool in CAMEO multiple times. These samples may help us understand how Crohn's disease responds to anti-TNF therapy.

Your sample goes to a state-of-the-art lab at Emory University in Atlanta, Georgia. Some samples will then be sent to other labs and facilities in North America for research tests.

It can be inconvenient to collect a stool sample. The home stool collection kits are hopefully a big help to you.

Thank you! Your participation makes the difference towards our goal to help put future pediatric patients on a faster path to Crohn's disease remission.